Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03395197 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 10, 2018
Last Update Posted : May 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| mCRPC | Drug: Talazoparib with enzalutamide Drug: Placebo with enzalutamide | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1125 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Double-blind. |
| Primary Purpose: | Treatment |
| Official Title: | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
| Actual Study Start Date : | December 18, 2017 |
| Actual Primary Completion Date : | October 3, 2022 |
| Estimated Study Completion Date : | July 31, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Combination arm
Talazoparib plus enzalutamide
|
Drug: Talazoparib with enzalutamide
Talazoparib 0.5 mg/day plus enzalutamide 160mg/day |
|
Active Comparator: Monotherapy arm
Ezalutamide plus placebo
|
Drug: Placebo with enzalutamide
Placebo plus enzalutamide 160 mg/day |
- Confirm the dose of Talazoparib (part 1) [ Time Frame: Day 1 up to 28 days ]determined based on the safety profile
- Radiographic PFS (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 25 months ]time from the date of randomization to first objective evidence of radiographic progression by blinded independent review, or death (occurring within 168 days of treatment discontinuation), whichever occurs first
- Overall survival (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]time from randomization to death from any cause
- Objective response in measurable soft tissue disease (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 6 months ]proportion of patients with measurable soft tissue disease at baseline with objective response per RECIST 1.1
- Duration of soft tissue response (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]duration of responses in patients with measurable soft tissue disease at baseline per RECIST 1.1
- PSA response (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]proportion of patients with PSA response grater than or equal to 50%
- Time to PSA progression (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]time from baseline to PSA progression
- Time to initiation of cytotoxic chemotherapy (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]time from randomization to initiation of cytotoxic chemotherapy
- Time to initiation of antineoplastic therapy (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]time from randomization to initiation of antineoplastic treatment
- Time to first symptomatic skeletal event (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]time from randomization to first symptomatic skeletal event (symptomatic fractures, spinal cord compression, surgery or radiation to the bone whichever is first)
- PFS on next line of therapy (PFS2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]PFS2 based on investigator assessment
- Opiate use for cancer pain (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]time from randomization to opiate use for prostate cancer pain
- Incidence of adverse events (part 1 and 2) [ Time Frame: Day 1 up to 26 months ]AEs and SAEs incidence by type and severity (graded by NCI CTCAE version 4.03)
- Pharmacokinetic assessment of talazoparib (part 1) [ Time Frame: Week 1, 5, 9, and 13 ]plasma concentration of talazoparib
- Pharmacokinetic assessment of talazoparib (part 2) [ Time Frame: week 3, 5, 9 13, and 17 ]plasma concentration of talazoparib
- Pharmacokinetic assessment of enzalutamide (part 1) [ Time Frame: week 1, 5, 9, and 13 ]plasma concentration of enzalutamide
- Pharmacokinetic assessment of enzalutamide (part 2) [ Time Frame: week 3, 5, 9 13, and 17 ]plasma concentration of enzalutamide
- Patient-reported outcome:pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]change from baseline in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)
- Patient-reported outcome: pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]time to deterioration in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)
- Patient-reported outcome: cancer specific global health status/QoL, functioning, and symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]change from baseline in patient-reported Global health status/QoL per EORTC QLQ-C30
- Patient-reported outcome: cancer specific global health status/QoL, functioning, and symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30
- Patient-reported outcome: general health status (part2) in unselected patients and patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]change from baseline in patient-reported general health status per EQ-5D-5L
- Patient-reported outcome: general health status (part 2) in unselected patients and patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]time to definitive deterioration in patient-reported disease-specific urinary symptoms per EORTC QLQ-PR25
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Men at least 18 years of age. For Japan, at least 20 years of age. |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features
Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4).
For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status
Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).
Surgically or medically castrated, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.
Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.
Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:
- Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..
- Soft tissue disease progression as defined by RECIST 1.1.
- Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.
Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
Life expectancy ≥ 12 months as assessed by the investigator.
Able to swallow the study drug and have no known intolerance to study drugs or excipients.
Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.
Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.
Evidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state.
Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.
Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.
Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).
Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).
Treatment with any investigational agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).
Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).
Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).
Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).
Clinically significant cardiovascular disease
Significant renal dysfunction as defined by any of the following laboratory abnormalities:
• Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via www.mdrd.com).
Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.
Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:
- Total serum bilirubin >1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).
- Albumin <2.8 g/dL
Absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).
Known or suspected brain metastasis or active leptomeningeal disease.
Symptomatic or impending spinal cord compression or cauda equina syndrome.
Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior malignancy except any of the following:
- Carcinoma in situ or non melanoma skin cancer
- Any prior malignancies ≥3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage.
- Stage 0 or Stage 1 cancer <3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator
Gastrointestinal disorder affecting absorption.
Fertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product.
Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395197
Show 360 study locations
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT03395197 |
| Other Study ID Numbers: |
C3441021 2017-003295-31 ( EudraCT Number ) TALAPRO-2 ( Other Identifier: Alias Study Number ) |
| First Posted: | January 10, 2018 Key Record Dates |
| Last Update Posted: | May 19, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
| URL: | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
mCRPC (metastatic castration-resistant prostate cancer) |
|
Talazoparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |